Featured Article
"Is the Coronavirus (COVID-19) Pandemic an Indication to Temporarily Modify Dermatological Management Plans?"
While the world lives under the shadow of the novel coronavirus (COVID-19) pandemic, dermatologists wonder if the current situation calls for a temporary change in the management of skin conditions.
Immunosuppressive drugs are used ubiquitously in the modern treatment of inflammatory and autoimmune skin diseases like psoriasis, bullous diseases, connective tissue diseases, and many others. Treatment of these conditions is based on the suppression of the patient’s immune system using steroids, steroid-sparing drugs, and biological agents.1
“The use of immunosuppressive to treat these conditions can amplify this effect, and it might leave the patient vulnerable to more serious complications should an infection with the novel coronavirus be established. Hence, it may be wise to restrict temporarily the use of immunosuppressive agents including systemic steroids, steroid-sparing agents, and biologics in dermatology daily practice until more evidence is avilable about their safety in the current pandemic.6 As a relates point, the International Psoriasis Council declared an urgent statement on March 11, 2020 that the physician should be alert to the potentially harmful effects of COVID-19 infection on patients with psoriasis and to immediately discontinue or postpone immunosuppressant medications for psoriasis patients diagnosed with COVID-19 disease.”
As the declaration of the novel coronavirus as a pandemic by the WHO is a trending topic nowadays, dermatologists around the world view with concern the impact of this pandemic on their daily practice.
Read Full Article Now
You May Also Like
Nourishing the Skin: A Review of Diet’s Role in Hidradenitis Suppurativa
What patients eat matters in HS: pro‑inflammatory diets worsen disease; anti‑inflammatory patterns and targeted supplements may help This literature review synthesizes recent studies connecting dietary patterns with hidradenitis suppurativa severity.…
Management of Hailey-Hailey Disease With Ruxolitinib 1.5% Cream
Case report shows symptom improvement with 1.5% ruxolitinib cream after standard therapies failed A 72‑year‑old woman with refractory Benign Familial Pemphigus (Hailey‑Hailey disease) experienced persistent flares despite conventional management with…
